The risk of tachyarrhythmias in patients with moderate-to-severe chronic kidney disease receiving tiotropium bromide

被引:4
|
作者
Mathioudakis, Alexander G. [1 ,2 ,3 ]
Mastoris, Ioannis [3 ,4 ]
Chatzimavridou-Grigoriadou, Victoria [2 ,3 ]
Mathioudakis, Georgios A. [2 ]
机构
[1] Aintree Univ Hosp NHS Fdn Trust, Chest Ctr, Liverpool L9 7AL, Merseyside, England
[2] Athens Breath Ctr, Athens, Greece
[3] Hellen Soc Adv Biomed Res, Resp Assembly, Athens, Greece
[4] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA
关键词
Tiotropium; Arrhythmia; Mortality; COPD; Therapeutics; Human; COPD; HANDIHALER; MORTALITY; RESPIMAT; INHALER;
D O I
10.1016/j.ijcard.2015.06.051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:105 / 106
页数:2
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF ORAL FEBUXOSTAT COMPARED TO ALLOPURINOL IN SUBJECTS WITH MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE
    Filiopoulos, Vassilis
    Manolios, Nikolaos
    Hadjiyannakos, Dimitrios
    Arvanitis, Dimitrios
    Karatzas, Ioannis
    Vlassopoulos, Dimosthenis
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 156 - 157
  • [32] Effect of moderate-to-severe chronic kidney disease on flow-mediated dilation and progenitor cells
    Kuczmarski, James M.
    Darocki, Mark D.
    DuPont, Jennifer J.
    Sikes, Robert A.
    Cooper, Carlton R.
    Farquhar, William B.
    Edwards, David G.
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2011, 236 (09) : 1085 - 1092
  • [33] Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review
    John R. Hurst
    MeiLan K. Han
    Barinder Singh
    Sakshi Sharma
    Gagandeep Kaur
    Enrico de Nigris
    Ulf Holmgren
    Mohd Kashif Siddiqui
    Respiratory Research, 23
  • [34] Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review
    Hurst, John R.
    Han, MeiLan K.
    Singh, Barinder
    Sharma, Sakshi
    Kaur, Gagandeep
    de Nigris, Enrico
    Holmgren, Ulf
    Siddiqui, Mohd Kashif
    RESPIRATORY RESEARCH, 2022, 23 (01)
  • [35] Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease
    Friedman, Daniel J.
    Singh, Jagmeet P.
    Curtis, Jeptha P.
    Tang, W. H. Wilson
    Bao, Haikun
    Spatz, Erica S.
    Hernandez, Adrian F.
    Patel, Uptal D.
    Al-Khatib, Sana M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (23) : 2618 - 2629
  • [36] Effectiveness and Safety of Rivaroxaban Vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation and Moderate-to-Severe Chronic Kidney Disease
    Coleman, Craig I.
    Martinez, Brandon K.
    Turpie, Alexander G. G.
    Sood, Nitesh
    Bunz, Thomas J.
    Kreutz, Reinhold
    BLOOD, 2017, 130
  • [37] BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) HEALTHCARE COSTS IN PATIENTS WITH MODERATE-TO-SEVERE DISEASE
    Lubwama, R.
    Mayen, Herrera E.
    Petruski-Ivleva, N.
    Hawaldar, K.
    Madziva, D.
    Qureshi, T.
    Cheng, W. H.
    VALUE IN HEALTH, 2024, 27 (12) : S98 - S98
  • [38] Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
    Mastorino, Luca
    Siliquini, Niccolo
    Avallone, Gianluca
    Ortoncelli, Michela
    Quaglino, Pietro
    Dapavo, Paolo
    Ribero, Simone
    DERMATOLOGY REPORTS, 2022, 14 (03)
  • [39] Determinants of thromboxane biosynthesis in patients with moderate to severe chronic kidney disease
    Vazzana, Natale
    Santilli, Francesca
    Lattanzio, Stefano
    Liani, Mario
    Giacci, Luciano
    Del Rosso, Goffredo
    Salvati, Filippo
    Boccatonda, Andrea
    Ferroni, Patrizia
    Davi, Giovanni
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2016, 33 : 74 - 80
  • [40] Management of Moderate-to-Severe Dyspnea in Hospitalized Patients Receiving Palliative Care
    Gomutbutra, Patama
    O'Riordan, David L.
    Pantilat, Steven Z.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2013, 45 (05) : 885 - 891